Cargando…
Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study
BACKGROUND: Chimeric antigen receptor T- Cell (CAR-T) immunotherapy has been a breakthrough treatment for various hematological malignancies. However, cardiotoxicities such as new-onset heart failure, arrhythmia, acute coronary syndrome and cardiovascular death occur in 10–15% of patients treated wi...
Autores principales: | Lee, Dae Hyun, Chandrasekhar, Sanjay, Jain, Michael D., Mhaskar, Rahul, Reid, Kayla, Lee, Sae Bom, Corallo, Salvatore, Hidalgo-Vargas, Melanie J., Kumar, Abhishek, Chavez, Julio, Shah, Bijal, Lazaryan, Aleksandr, Khimani, Farhad, Nishihori, Taiga, Bachmeier, Christina, Faramand, Rawan, Fradley, Michael G., Jeong, Daniel, Oliveira, Guilherme H., Locke, Frederick L., Davila, Marco L, Alomar, Mohammed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067156/ https://www.ncbi.nlm.nih.gov/pubmed/37005652 http://dx.doi.org/10.1186/s40959-023-00170-5 |
Ejemplares similares
-
Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL
por: Perez, Ariel, et al.
Publicado: (2022) -
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
por: Lee, Dae Hyun, et al.
Publicado: (2023) -
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
por: Logue, Jennifer M., et al.
Publicado: (2020) -
PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Mohammed, Turab, et al.
Publicado: (2023) -
Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac Lymphoma
por: Lee, Dae Hyun, et al.
Publicado: (2022)